Valuation : Cerenome, Inc.

Market Cap 22.92M 19.67M 18.46M 16.86M 31.83M 2.19B 31.98M 219M 84.68M 1.1B 86.06M 84.19M 3.65B P/E 2026 *
-0.6x
P/E 2027 * -1.26x
Enterprise Value 22.92M 19.67M 18.46M 16.86M 31.83M 2.19B 31.98M 219M 84.68M 1.1B 86.06M 84.19M 3.65B EV / Sales 2026 *
2.43x
EV / Sales 2027 * 1.2x
Free-Float
98.2%
Yield 2026 *
-
Yield 2027 * -
1 day-2.11%
1 week-5.33%
Current month-21.96%
1 month-21.15%
3 months-54.24%
6 months-62.75%
Current year-76.42%
1 week 2.92
Extreme 2.92
3.12
1 month 2.92
Extreme 2.92
4.16
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
862.5
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 2014-04-01
Director of Finance/CFO 52 2020-02-05
Chief Tech/Sci/R&D Officer - 2025-10-20
Director TitleAgeSince
Director/Board Member 64 2002-09-30
Chairman 77 2018-01-24
Director/Board Member 66 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Director

1,844 0.0269%
7/1/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
7/1/26 Fiscal year

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%-5.33%-76.09%-95.15% 22.92M
-0.71%-0.24%+2.10%+22.90% 50.96B
+1.92%+0.36%+477.97%+550.09% 46.18B
-0.15%-0.28%+21.65%+89.41% 42.73B
+0.81%+4.91%+39.28%+19.41% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
+0.81%+1.77%+31.91%+138.26% 17.28B
-1.08%-3.61% - - 16.43B
-0.66%-0.66%+11.02%+27.72% 14.73B
-0.85%+1.76%+80.26%+47.26% 14.09B
Average -0.67%+0.67%+66.92%+94.60% 27.89B
Weighted average by Cap. -0.47%+1.16%+103.28%+138.70%

Financials

2026 *2027 *
Net sales 9.44M 8.1M 7.6M 6.95M 13.11M 900M 13.17M 89.99M 34.87M 454M 35.44M 34.67M 1.5B 19.14M 16.43M 15.42M 14.08M 26.58M 1.83B 26.71M 182M 70.72M 921M 71.87M 70.31M 3.05B
Net income -34.22M -29.37M -27.56M -25.18M -47.51M -3.26B -47.74M -326M -126M -1.65B -128M -126M -5.45B -18.45M -15.84M -14.87M -13.58M -25.63M -1.76B -25.75M -176M -68.18M -888M -69.29M -67.79M -2.94B
Net Debt - -
Logo Cerenome, Inc.
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
28
Date Price Change Volume
26-08-26 US$3.020 -2.11% 18,058
26-08-25 US$3.085 +4.22% 29,629
26-08-24 US$2.960 -3.58% 44,559
26-08-21 US$3.070 +2.33% 106,240
26-08-20 US$3.000 -5.96% 54,467
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.020USD
Average target price
36.00USD
Spread / Average Target
+1,092.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNSY Stock